New clinical study to broaden the use of TUBEX® TF on the African market
Kurs
-3,23%
Likviditet
0,39 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | N/A | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2025-05-15 | N/A | Årsstämma |
| 2025-05-07 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-19 | - | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-23 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2024-05-22 | - | Årsstämma |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2023-05-24 | - | Årsstämma |
| 2023-05-03 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2022-01-19 | - | Extra Bolagsstämma 2022 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-31 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-03 | - | Extra Bolagsstämma 2021 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-07 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2021-05-06 | - | Årsstämma |
| 2021-02-19 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | Kvartalsrapport 2020-Q1 |
| 2020-05-07 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2020-05-06 | - | Årsstämma |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Extra Bolagsstämma 2019 |
| 2019-11-05 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-17 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-11-09 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-18 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2018-06-15 | - | Årsstämma |
| 2018-04-27 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-19 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2017-05-18 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-19 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2016-05-18 | - | Årsstämma |
| 2016-05-10 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-16 | - | Bokslutskommuniké 2015 |
| 2015-11-10 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-25 | - | Kvartalsrapport 2015-Q2 |
| 2015-06-04 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2015-06-03 | - | Årsstämma |
| 2015-05-28 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-17 | - | Bokslutskommuniké 2014 |
| 2014-11-18 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-19 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-08 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2014-05-07 | - | Årsstämma |
| 2014-05-05 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-18 | - | Bokslutskommuniké 2013 |
| 2013-11-27 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-21 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-06 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2013-05-03 | - | Årsstämma |
| 2013-04-24 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-19 | - | Bokslutskommuniké 2012 |
| 2012-11-20 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-21 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-13 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2012-06-12 | - | Årsstämma |
| 2012-05-22 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-05 | - | Extra Bolagsstämma 2012 |
| 2012-02-09 | - | Bokslutskommuniké 2011 |
| 2011-10-17 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-17 | - | Kvartalsrapport 2011-Q2 |
| 2011-06-01 | - | Kvartalsrapport 2011-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
AroCell announces today that a new evaluation study of the TUBEX® TF product starts in Uganda. This study will be conducted in collaboration with the Uganda National Public Health Laboratory Services (UNHLS). The study is carried out for documentation of TUBEX® TF and will after a positive outcome work as a basis for market approval and sales.
“AroCell is actively working to establish TUBEX in several African markets. Given positive study results, our distributor Medilink Lab and Surgicals Limited can start sales in Uganda. The study is estimated to be completed within 6-12 months", says Anders Hultman, AroCells CEO.
TUBEX® TF is a bacteriological rapid test for a simple and safe diagnosis of typhoid fever, the most serious form of salmonella. Typhoid fever is a water- and food-borne infectious disease that can be fatal if the correct diagnosis is not made and treatment is initiated. According to the WHO, 11–20 million new cases are diagnosed annually, of which more than 160,000 lead to deaths, mainly among children.
Typhoid fever causes high fever, flu-like symptoms, and severe diarrhea, and is potentially life-threatening if not treated properly. Due to the symptoms, the patient may be misdiagnosed with diseases such as malaria, dengue fever, or pneumonia. As typhoid fever is treated with antibiotics and antibiotic resistance is, unfortunately, a growing problem, rapid testing, and correct diagnosis is a further argument for the need.
About AroCell
AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare and established in various markets. In oncology, AroCell uses various biomarkers, TK1 and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com